Lupus & antiphospholipid syndrome
Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis
Authors' conclusion
Predominantly observational data suggest a potential cardiovascular benefit of SGLT2 inhibitors in rheumatic IMIDs, but the available evidence is confined largely to SLE and SSc populations. Whilst SGLT2 inhibitors should be used in established indications of type 2 diabetes mellitus, heart failure and chronic kidney disease, prospective and controlled studies in IMID populations are needed to establish their cardiovascular benefit, clarify safety and evaluate for effect on disease activity.
Study context
- Population
- Adults with rheumatic immune-mediated inflammatory diseases (IMIDs) using SGLT2i, predominantly systemic lupus erythematosus and systemic sclerosisIMID participants in five studies, systemic sclerosis (SSc) 25.4%, systemic lupus erythematosus (SLE) 70.9%, other IMIDs 3.9%
- Participants
- 11,190 adults
- Comparison
- SGLT2i use in IMID patients
- Outcome
- All-cause mortality and heart failure risk (three studies reporting major adverse cardiovascular events (MACE))
Methodological detailsFollowing PRISMA guidance, observational and interventional adult IMID studies
- Following PRISMA guidance
- Observational and interventional adult IMID studies
Pooled result
As reported in the abstract
- SGLT2i use was associated with lower all-cause mortality and heart failure risk
Further pooled results
Myocardial infarction
- No clear effect on myocardial infarction
Hospitalisation, treatment discontinuation and IMID flare
- Evidence limited and inconsistent
Original publication
Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis. Semin Arthritis Rheum. Published 22 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →